The global smart inhalers market size was estimated to be USD 15.56 billion in 2023 and is expected to reach at USD 109.01 billion by 2034 with a CAGR of 19.36% during the forecast period 2024-2034. Surge in prevalence of chronic respiratory diseases (CRDs), the presence of improved clinical results, increasing demand for advanced digital devices and solutions for respiratory and pulmonary healthcare, growing emphasis on the advancement of smart inhalers, rise in initiatives by major market players to support research and development endeavors, surge in number of companies are incorporating digital technologies into their product portfolios to improve the efficiency of medication & the management of conditions such as asthma & COPD, and increasing introduction of innovative smart inhaler devices are some of the key factors boosting the market growth.
Increasing introduction of innovative smart inhaler devices is predicted to boost the market growth during the forecast period. Smart inhalers are devices designed for the administration of various drugs via inhalation. These drugs can include anti-cholinergic medications, glucocorticoids, insulin, and beta-agonists, which are commonly used in inhalers to manage and prevent respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). These inhalers are referred to as "smart inhalers" because they incorporate sensors that can be attached as a clip to the inhaler, monitoring the correct dosage per use and the inhalation technique employed to administer the medication. The data collected by the sensor is then shared with both the patient and healthcare professionals, enabling them to monitor inhaler usage. Consequently, market players are increasingly focused on developing innovative smart inhaler devices. For instance, in February 2022, Aptar Pharma, a prominent global provider of drug delivery systems, services, and advanced material science solutions, has unveiled HeroTracker Sense, an innovative digital respiratory health solution. This technology converts a regular metered dose inhaler (pMDI) into a intelligent, connected healthcare device.
By type, metered dose inhalers (MDI) was the highest revenue-grossing segment in the global smart inhalers market in 2023 as they are efficient & user-friendly, delivering a fixed dose in quick bursts through inhalation, typically self-administered by the patient. in September 2022, The research lab OzUK Limited, based in the U.K., has joined forces with H&T Presspart to introduce generic Metered-Dose Inhalers (MDIs) for traditional applications related to asthma and chronic obstructive pulmonary disease (COPD). This partnership will enhance H&T Presspart's existing Inhalation Product Technology Centre (IPTC) services, granting H&T Presspart's customers a comprehensive set of options for developing and launching MDIs with conventional propellants, in addition to the new low Global Warming Potential (GWP) propellants, HFA 152a and HFO1234ze. Additionally, dry powdered inhalers (DPIs) is predicted to grow at fastest CAGR during the forecast period owing to the increasing environmental concerns regarding inhaler devices that utilize chlorofluorocarbons as propellants, Dry Powder Inhalers (DPIs) are now favored over pressurized Metered-Dose Inhalers (MDIs) and nebulizers for the treatment of respiratory conditions.
By indication, chronic obstructive pulmonary disease (COPD) was the highest revenue-grossing segment in the global smart inhalers market in 2023 owing to the increasing prevalence of COPD and growing regulatory approvals of advanced devices. For instance, in April 2023, Vivera, a science-focused biopharmaceutical and medical technology firm, is delighted to announce that the U.K. Intellectual Property Office (IPO) has approved the patent for the Company's ZICOH device. This further fortifies the company's global intellectual property presence in the United Kingdom, affirming the device's rights as a smart inhaler with automated dose delivery, measurement, and management capabilities. Additionally, asthma is predicted to grow at fastest CAGR during the forecast period owing to the surge in hospital admissions for asthma, particularly among young children and increasing adoption of smart technologies.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global smart inhalers market in 2023 owing to the growing incidence of CRDs, surge in geriatric population which is frequently admitted to hospitals for various chronic respiratory conditions & often opt to obtain their medications from hospital pharmacies, and rising launch of new devices. For instance, in July 2023, Teva has introduced The GoResp Digihaler, a digitally-enabled inhaler, in the United Kingdom, marking the first European market where the device is available. This inhaler is designed for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to comfort, flexibility, & convenience, increasing preference for retail pharmacies more among customers, and rapid expansion & modernization of current pharmacies to enhance their market presence.
By end-user, hospitals was the highest revenue-grossing segment in the global smart inhalers market in 2023 owing to the expansion of public-private partnerships, rapid progress in healthcare infrastructure, and improved access to healthcare services. Additionally, home care settings is predicted to grow at fastest CAGR during the forecast period owing to the increasing cost of healthcare, many individuals with Chronic Respiratory Diseases (CRDs) opt for home-based treatment, rising inclination among elderly patients to receive care in the comfort of their own homes, and growing focus on development of innovative products. For instance, in January 2023, Aseptika has been granted an Innovate UK Smart Award to create a Smart Inhaler Tracker for individuals with lung health conditions. This award will support the company in developing its third-generation smart inhaler tracker, which will incorporate 5G mobile connectivity.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in prevalence of COPD & asthma, increasing research & development activities, and growing collaborations within key market players. For example, in August 2022, Adherium Limited, a significant player in the respiratory eHealth and data management sector, has unveiled a partnership with Trudell Medical Limited to support COPD patients in the United States. In this collaboration, both companies will assess COPD patients following their hospital discharge. They will utilize Trudell's U.S. operation, Monaghan Medical, and its subsidiary Aetonix's aTouchAway platform, in combination with Adherium's Hailie sensors, with the objective of decreasing readmissions and improving patient outcomes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in elderly population, growing incidence of CRDs, rising healthcare infrastructure, increasing government initiatives, and surge in launch of new products. For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited has introduced Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the initial single-inhaler triple therapy (SITT) in India for patients with Chronic Obstructive Pulmonary Disease (COPD). This therapy offers a once-daily regimen.
Increasing introduction of innovative smart inhaler devices is predicted to boost the market growth during the forecast period. Smart inhalers are devices designed for the administration of various drugs via inhalation. These drugs can include anti-cholinergic medications, glucocorticoids, insulin, and beta-agonists, which are commonly used in inhalers to manage and prevent respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). These inhalers are referred to as "smart inhalers" because they incorporate sensors that can be attached as a clip to the inhaler, monitoring the correct dosage per use and the inhalation technique employed to administer the medication. The data collected by the sensor is then shared with both the patient and healthcare professionals, enabling them to monitor inhaler usage. Consequently, market players are increasingly focused on developing innovative smart inhaler devices. For instance, in February 2022, Aptar Pharma, a prominent global provider of drug delivery systems, services, and advanced material science solutions, has unveiled HeroTracker Sense, an innovative digital respiratory health solution. This technology converts a regular metered dose inhaler (pMDI) into a intelligent, connected healthcare device.
By type, metered dose inhalers (MDI) was the highest revenue-grossing segment in the global smart inhalers market in 2023 as they are efficient & user-friendly, delivering a fixed dose in quick bursts through inhalation, typically self-administered by the patient. in September 2022, The research lab OzUK Limited, based in the U.K., has joined forces with H&T Presspart to introduce generic Metered-Dose Inhalers (MDIs) for traditional applications related to asthma and chronic obstructive pulmonary disease (COPD). This partnership will enhance H&T Presspart's existing Inhalation Product Technology Centre (IPTC) services, granting H&T Presspart's customers a comprehensive set of options for developing and launching MDIs with conventional propellants, in addition to the new low Global Warming Potential (GWP) propellants, HFA 152a and HFO1234ze. Additionally, dry powdered inhalers (DPIs) is predicted to grow at fastest CAGR during the forecast period owing to the increasing environmental concerns regarding inhaler devices that utilize chlorofluorocarbons as propellants, Dry Powder Inhalers (DPIs) are now favored over pressurized Metered-Dose Inhalers (MDIs) and nebulizers for the treatment of respiratory conditions.
By indication, chronic obstructive pulmonary disease (COPD) was the highest revenue-grossing segment in the global smart inhalers market in 2023 owing to the increasing prevalence of COPD and growing regulatory approvals of advanced devices. For instance, in April 2023, Vivera, a science-focused biopharmaceutical and medical technology firm, is delighted to announce that the U.K. Intellectual Property Office (IPO) has approved the patent for the Company's ZICOH device. This further fortifies the company's global intellectual property presence in the United Kingdom, affirming the device's rights as a smart inhaler with automated dose delivery, measurement, and management capabilities. Additionally, asthma is predicted to grow at fastest CAGR during the forecast period owing to the surge in hospital admissions for asthma, particularly among young children and increasing adoption of smart technologies.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global smart inhalers market in 2023 owing to the growing incidence of CRDs, surge in geriatric population which is frequently admitted to hospitals for various chronic respiratory conditions & often opt to obtain their medications from hospital pharmacies, and rising launch of new devices. For instance, in July 2023, Teva has introduced The GoResp Digihaler, a digitally-enabled inhaler, in the United Kingdom, marking the first European market where the device is available. This inhaler is designed for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to comfort, flexibility, & convenience, increasing preference for retail pharmacies more among customers, and rapid expansion & modernization of current pharmacies to enhance their market presence.
By end-user, hospitals was the highest revenue-grossing segment in the global smart inhalers market in 2023 owing to the expansion of public-private partnerships, rapid progress in healthcare infrastructure, and improved access to healthcare services. Additionally, home care settings is predicted to grow at fastest CAGR during the forecast period owing to the increasing cost of healthcare, many individuals with Chronic Respiratory Diseases (CRDs) opt for home-based treatment, rising inclination among elderly patients to receive care in the comfort of their own homes, and growing focus on development of innovative products. For instance, in January 2023, Aseptika has been granted an Innovate UK Smart Award to create a Smart Inhaler Tracker for individuals with lung health conditions. This award will support the company in developing its third-generation smart inhaler tracker, which will incorporate 5G mobile connectivity.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in prevalence of COPD & asthma, increasing research & development activities, and growing collaborations within key market players. For example, in August 2022, Adherium Limited, a significant player in the respiratory eHealth and data management sector, has unveiled a partnership with Trudell Medical Limited to support COPD patients in the United States. In this collaboration, both companies will assess COPD patients following their hospital discharge. They will utilize Trudell's U.S. operation, Monaghan Medical, and its subsidiary Aetonix's aTouchAway platform, in combination with Adherium's Hailie sensors, with the objective of decreasing readmissions and improving patient outcomes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in elderly population, growing incidence of CRDs, rising healthcare infrastructure, increasing government initiatives, and surge in launch of new products. For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited has introduced Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the initial single-inhaler triple therapy (SITT) in India for patients with Chronic Obstructive Pulmonary Disease (COPD). This therapy offers a once-daily regimen.
Segmentation: Smart Inhalers Market Report 2023 - 2034
Smart Inhalers Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Metered Dose Inhalers (MDIS)
- Dry Powdered Inhalers (DPIS)
Smart Inhalers Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Others
Smart Inhalers Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Smart Inhalers Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Home Care Settings
- Hospitals
- Others
Smart Inhalers Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Smart Inhalers Market: Type Estimates & Trend Analysis
8. Smart Inhalers Market: Indication Estimates & Trend Analysis
9. Smart Inhalers Market: Distribution Channel Estimates & Trend Analysis
10. Smart Inhalers Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Smart Inhalers Market
13. Europe Global Smart Inhalers Market
14. Asia Pacific Global Smart Inhalers Market
15. Latin America Global Smart Inhalers Market
16. MEA Global Smart Inhalers Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Propeller Health
- H&T Presspart Manufacturing Ltd.
- Novartis AG
- Cognita Labs
- 3M Health Care Limited
- Adherium Limited
- Teva Pharmaceuticals Industries Ltd.
- FindAir Sp. z o.o
- Pneuma Respiratory Inc.
- AireHealth Inc.
- COHERO Health Inc.
- Amiko Digital Health Limited
- Personal Air Quality Systems Private Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 15.56 Billion |
| Forecasted Market Value ( USD | $ 109.01 Billion |
| Compound Annual Growth Rate | 19.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
